Acrivon Therapeutics, Inc. — Form 8-K
Filed November 6, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Acrivon acquired ACR-525 (a Phase 2-ready oral JAK1 inhibitor) and a PKC-theta inhibitor preclinical program from Aqilion AB for undisclosed cash consideration with no royalties or milestones. The deal establishes immunology and inflammation as a strategic pillar alongside oncology; ACR-525 targets eosinophilic esophagitis first, with potential in IBD and autoimmune diseases. Concurrently, Acrivon terminated all future royalty and milestone obligations between Aqilion and LEO Pharma on ACR-525.
Why this rating
Transformational pipeline expansion into I&I for $20.4M-market-cap company; Phase 2-ready asset materially diversifies oncology focus; undisclosed price unknown but asset value likely material relative to company size.
Tradability signal
NO TRADE
No trade: positive news with only -2.8% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: -0.53% over 4 hrs, n=382). (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
at our read · unknown $1.53 | +10 min · unknown $1.52 ▼ 0.65% | +30 min · unknown $1.57 ▲ 2.94% | +1 hr · unknown $1.54 ▲ 0.65% | +4 hrs · unknown $1.56 ▲ 2.29% |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.